ORIC Pharmaceuticals, Inc , a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.
infoORIC Pharmaceuticals is a small cap stock with a total market cap of 490.25M.
infoThey trade on the NASDAQ and had their IPO 3 years and 3 months ago.
infoORIC Pharmaceuticals currently employs 89 people.
infoAs of Wednesday, Aug 23 2023, ORIC Pharmaceuticals’s share price is $8.99.
News Relating to ORIC Pharmaceuticals
Market Watch
You can still run with the stock market’s bulls, but watch the exits
Thursday Jul 27 2023 at 15:57
The stock market, as measured by the S&P 500 Index SPX, -0.64% ), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is a bit of an overbought condition, but not a sell signal.
The Motley Fool
Why Shares of Oric Pharmaceuticals Jumped Monday
Monday Jun 26 2023 at 13:04
Oric Pharmaceuticals specializes in oncology therapies. The company said the private placement will help it fund operations through the end of 2025.
GlobeNewsWire
ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference
Tuesday Apr 25 2023 at 16:30
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.
InvestorPlace
The 7 Best Biotech Stocks for Personalized Medicine Investors
Tuesday Apr 25 2023 at 06:35
Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person’s body.
Seeking Alpha
ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets
Wednesday Mar 15 2023 at 00:47
ORIC has a few early stage cancer targeting molecules. In December, Pfizer made a small $25mn deal with it for the lead asset.
GlobeNewsWire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Wednesday Feb 01 2023 at 16:30
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:
GlobeNewsWire
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
Tuesday Jan 03 2023 at 16:30
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 11:15 a.m. PT.
PennyStocks
New Years Penny Stocks Trading Advice: 3 Tips
Friday Dec 23 2022 at 06:00
What you need to know about trading penny stocks as the year ends The post New Years Penny Stocks Trading Advice: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Zacks Investment Research
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
Thursday Dec 22 2022 at 12:48
ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter’s elranatamab in multiple myeloma. Stock up in after-hours trading.
Market Watch
Oric’s stock rallies on multiple myeloma deal with Pfizer
Thursday Dec 22 2022 at 08:38
Shares of Oric Pharmaceuticals Inc. ORIC, +2.04% soared about 56% in premarket trading on Thursday, the day after the company said it will collaborate with Pfizer Inc. PFE, +0.66% to develop a multiple myeloma therapeutic candidate. Pfizer will pay $4.65 per share for 5,376,344 of Oric’s common shares, for a total of $25 million.
InvestorPlace
ORIC Pharmaceuticals (ORIC) Stock Rockets 58% on Pfizer Deal
Thursday Dec 22 2022 at 08:25
ORIC Pharmaceuticals (NASDAQ: ORIC ) stock is rocketing higher after the company revealed a collaboration deal with Pfizer (NYSE: PFE ). The big news here is ORIC Pharmaceuticals and Pfizer working together on the development of ORIC-533.
GlobeNewsWire
ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Tuesday Nov 08 2022 at 16:10
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 5:35 p.m. GMT.
Seeking Alpha
ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Friday Oct 14 2022 at 09:43
Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023.
GlobeNewsWire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Thursday Sep 01 2022 at 16:15
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:
GlobeNewsWire
ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference
Thursday Jun 02 2022 at 16:10
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 8:00 a.m. ET.
GlobeNewsWire
ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Tuesday May 17 2022 at 16:10
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET.
InvestorPlace
7 Stocks That Insiders Are Buying Now. Should You?
Thursday Mar 31 2022 at 08:33
Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revolution Medicines (NASDAQ:RVMD) Sofi Technologies (NASDAQ:SOFI) The post 7 Stocks That Insiders Are Buying Now. Should You?
Zacks Investment Research
ORIC Stock Plunges on Discontinuation of Oncology Candidate
Wednesday Mar 23 2022 at 12:47
ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.
The Motley Fool
Why ORIC Pharmaceuticals Stock Is Crashing Today
Tuesday Mar 22 2022 at 11:51
The company discontinued development of its lead clinical program.
Benzinga
Why ORIC Pharmaceuticals Shares Are Plunging Today
Tuesday Mar 22 2022 at 09:33
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has decided to discontinue the further development of ORIC-101 after interim analyses from the two Phase 1b studies, wherein ORIC-101 did not demonstrate sufficient clinical activity. The dose-expansion portion of the Phase 1b trial of ORIC-.
Seeking Alpha
ORIC Pharmaceuticals, Inc.’s (ORIC) CEO Jacob Chacko on Q4 2021 Results – Earnings Call Transcript
Monday Mar 21 2022 at 20:48
ORIC Pharmaceuticals, Inc.’s (ORIC) CEO Jacob Chacko on Q4 2021 Results – Earnings Call Transcript
GlobeNewsWire
ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call
Thursday Mar 17 2022 at 16:30
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results and provide an operational update on Monday, March 21, 2022, at 5:00 p.m. ET.
GuruFocus
2 Falling Knives to Catch
Tuesday Feb 22 2022 at 12:44
Wall Street recommends purchasing shares of ORIC Pharmaceuticals Inc. ( ORIC , Financial) and Ondas Holdings Inc. ( ONDS , Financial). That sounds surprising given that these two stocks haven’t performed well over the past 52 weeks ending Feb. 18.
GlobeNewsWire
ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
Tuesday Jan 04 2022 at 16:30
SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET.
GlobeNewsWire
ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma
Thursday Dec 09 2021 at 16:30
Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Thursday Nov 11 2021 at 16:15
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences:
GlobeNewsWire
ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
Thursday Nov 04 2021 at 09:00
CD73 inhibition overcomes immune suppression and demonstrates activity in autologous ex vivo cell assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic
Benzinga
ORIC Pharma’s Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors
Thursday Oct 07 2021 at 15:24
ORIC Pharmaceuticals Inc (NASDAQ: ORIC) announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide. Data were presented at AACR-NCI-EORTC.
GlobeNewsWire
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC
Thursday Oct 07 2021 at 08:55
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide
GlobeNewsWire
ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Thursday Sep 30 2021 at 16:30
Company to host conference call and webcast Thursday, October 7, 2021, at 9:00 a.m. ET Company to host conference call and webcast Thursday, October 7, 2021, at 9:00 a.m. ET
ORIC Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
ORIC Pharmaceuticals’s Altman Z-score is 10.94 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
ORIC Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $125.50K of common stock in ORIC Pharmaceuticals on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
ORIC Pharmaceuticals’s Income Quality of 0.63 is in line with its Industry Group of 0.69 (-8.7% lower)
ORIC Pharmaceuticals’s Income Quality of 0.63 is lower than its Major Industry Group of 0.71 (-11.3% lower)
ORIC Pharmaceuticals’s Income Quality of 0.63 is lower than its Sector of 0.75 (-16.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
ORIC Pharmaceuticals’s Current Ratio of 18.46 is greater than its Industry Group of 4.76 (287.8% greater)
ORIC Pharmaceuticals’s Current Ratio of 18.46 is greater than its Major Industry Group of 4.32 (327.3% greater)
ORIC Pharmaceuticals’s Current Ratio of 18.46 is greater than its Sector of 2.6 (610.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-5.54 & -1.27)
Cannot compare a negative PE Ratio (-5.54 & -1.1)
Cannot compare a negative PE Ratio (-5.54 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
ORIC Pharmaceuticals’s PB Ratio of 1.82 is greater than its Industry Group of 1.34 (35.8% greater)
ORIC Pharmaceuticals’s PB Ratio of 1.82 is greater than its Major Industry Group of 1.4 (30.0% greater)
ORIC Pharmaceuticals’s PB Ratio of 1.82 is greater than its Sector of 1.62 (12.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
ORIC Pharmaceuticals’s ROE of -0.33 is greater than its Industry Group of -0.44 (25.0% greater)
ORIC Pharmaceuticals’s ROE of -0.33 is greater than its Major Industry Group of -0.38 (13.2% greater)
ORIC Pharmaceuticals’s ROE of -0.33 is lower than its Sector of -0.03 (-1000.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
ORIC Pharmaceuticals’s ROCE of -0.36 is greater than its Industry Group of -0.42 (14.3% greater)
ORIC Pharmaceuticals’s ROCE of -0.36 is in line with its Major Industry Group of -0.37 (2.7% greater)
ORIC Pharmaceuticals’s ROCE of -0.36 is lower than its Sector of -0.04 (-800.0% lower)
Derived from SEC.GOV filing dataopen_in_new